{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:24:48Z","timestamp":1745468688138,"version":"3.40.4"},"reference-count":27,"publisher":"S. Karger AG","issue":"10","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"abstract":"<jats:p>Introduction: Patients with hepatocellular carcinoma (HCC) and inferior vena cava tumor thrombus (IVCTT) have poor prognosis. Combination therapy involving the blockade of programmed cell death protein 1 (PD-1) and tyrosine kinase inhibitors is an efficient treatment strategy for advanced HCC. However, surgical treatment after a combination of systemic therapy and transarterial chemoembolization (TACE) for HCC with IVCTT has not been widely reported, and the efficacy and safety of this treatment have not been studied. Methods: In the 21 cases reported herein, the patients were treated with TACE, lenvatinib, and PD-1 blockade. The treatment responses, progression-free survival (PFS), overall survival (OS), disease control rate, and toxicities were evaluated, and the related literature was reviewed. Results: The overall response and disease control rates were 66.7% and 85.7%, respectively. The median PFS time was 16.0 months, with a 1-year PFS rate of 55.60%. The median OS was not reached, with a 1-year OS rate of 66.70%. Four patients underwent hepatectomy without serious complications and survived for 29.1, 24.7, 14.2, and 13.8 months. Three patients survived tumor-free, and 1 patient experienced intrahepatic recurrence. Pathological complete response and major pathological responses were observed in 1 and 3 patients, respectively. Treatment-related adverse events of any grade occurred in 8\/9 patients (88.9%), and grade 3 treatment-related adverse events occurred in 1 patient. Conclusion: The combination of TACE, lenvatinib, and PD-1 is effective for HCC with IVCTT and has acceptable adverse effects. <\/jats:p>","DOI":"10.1159\/000540662","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T21:17:50Z","timestamp":1723065470000},"page":"465-473","source":"Crossref","is-referenced-by-count":0,"title":["Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature Review"],"prefix":"10.1159","volume":"47","author":[{"given":"Yang-Kai","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De-Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Xin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Xiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Ye","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao-Lin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1713263"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2008.09.030"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.04.042"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12697"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29086"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0073-4"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.09.051"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00808"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1539"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29225"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.032"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32834dda64"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3264079"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-13-60"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.847601"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.709060"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S332420"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.9738\/INTSURG-D-14-00133.1"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6665-5"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-019-01077-4"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1159\/000514313"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00274-z"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.783480"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/ort\/article-pdf\/47\/10\/465\/4285931\/000540662.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/ort\/article-pdf\/47\/10\/465\/4285931\/000540662.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:33:44Z","timestamp":1745422424000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000540662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,4]]},"published-print":{"date-parts":[[2024,10,10]]}},"URL":"https:\/\/doi.org\/10.1159\/000540662","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"type":"print","value":"2296-5270"},{"type":"electronic","value":"2296-5262"}],"subject":[],"published":{"date-parts":[[2024,8,7]]}}}